The six small molecules can affect the immune signatures of LN by downregulating hub genes because 23 hub genes (IFI6, PLSCR1, XAF1, IFI16, IFI44, MX1, IFI44L, IFIT3, IFIT2, IFI27, DDX58, EIF2AK2, IFITM1, RTP4, IFITM3, TRIM22, PARP12, IFIH1, OAS1, HERC6, RSAD2, DDX60, and MX2) could emerge as the biomarkers and novel drug targets for the diagnosis and treatment of LN. This evidence concerns the gene IFIT2 and lobular neoplasia.